As part of its continuing effort to make the agency more transparent and accessible, the FDA has scheduled a series of workshops about orphan drug designation for academics, biotechnology companies, and those unfamiliar with the process. The FDA can grant a special status, known as orphan designation, for drug products intended to treat rare diseases.
Read original post here »
The health and medical information on our Web site is not intended to take the place of advice or treatment from healthcare professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.
All information found in this post are credit to the U.S. Food and Drug Administration. If you are looking for useful and updated information, you can visit U.S. for more press releases.
As part of its continuing effort to make the agency more transparent and accessible, the FDA has scheduled a series of workshops about orphan drug designation for academics, biotechnology companies, and those unfamiliar with the process. The FDA can grant a special status, known as orphan designation, for drug products intended to treat rare diseases.
Read original post here »
The health and medical information on our Web site is not intended to take the place of advice or treatment from healthcare professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.
All information found in this post are credit to the U.S. Food and Drug Administration. If you are looking for useful and updated information, you can visit U.S. for more press releases.
